Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
Cardiovasc Diabetol. 2021 Sep 8;20(1):180. doi: 10.1186/s12933-021-01370-y.
Patients with diabetes mellitus (DM) have a higher prevalence of heart failure (HF) than those without it. Approximately 40 % of HF patients have DM and they tend to have poorer outcomes than those without DM. This study evaluated the impact of insulin therapy on mortality among acute HF patients.
A total of 1740 patients from the Korean Acute Heart Failure registry with DM were included in this study. The risk of all-cause mortality according to insulin therapy was assessed using the Cox proportional hazard models with inverse probability of treatment weighting to balance the clinical characteristics (pretreatment covariates) between the groups.
DM patients had been treated with either oral hypoglycemic agents (OHAs) alone (n = 620), insulin alone (n = 682), or insulin combined with OHAs (n = 438). The insulin alone group was associated with an increased mortality risk compared with the OHA alone group (HR = 1.41, 95 % CI 1.21-1.66]). Insulin therapy combined with OHAs also showed an increased mortality risk (HR = 1.29, 95 % CI 1.14-1.46) compared with the OHA alone group. Insulin therapy was consistently associated with increased mortality risk, regardless of the left ventricular ejection fraction (LVEF) or HF etiology. A significant increase in mortality was observed in patients with good glycemic control (HbA1c < 7.0 %) receiving insulin, whereas there was no significant association in patients with poor glycemic control (HbA1c ≥ 7.0%).
Insulin therapy was found to be associated with increased mortality compared to OHAs. The insulin therapy was harmful especially in patients with low HbA1c levels which may suggest the necessity of specific management strategies and blood sugar targets when using insulin in patients with HF.
患有糖尿病(DM)的患者比没有糖尿病的患者更容易发生心力衰竭(HF)。大约 40%的 HF 患者患有 DM,他们的预后往往比没有 DM 的患者差。本研究评估了胰岛素治疗对急性 HF 患者死亡率的影响。
本研究共纳入了来自韩国急性心力衰竭登记处的 1740 例 DM 患者。使用 Cox 比例风险模型评估胰岛素治疗的全因死亡率风险,并使用逆概率治疗加权来平衡组间的临床特征(预处理协变量)。
DM 患者分别接受了单独口服降糖药(OHA)治疗(n=620)、单独胰岛素治疗(n=682)或胰岛素联合 OHA 治疗(n=438)。与单独 OHA 组相比,单独胰岛素组的死亡率风险增加(HR=1.41,95%CI 1.21-1.66)。与单独 OHA 组相比,胰岛素联合 OHA 治疗也显示出更高的死亡率风险(HR=1.29,95%CI 1.14-1.46)。无论左心室射血分数(LVEF)或 HF 病因如何,胰岛素治疗均与死亡率风险增加相关。在血糖控制良好(HbA1c<7.0%)的患者中,接受胰岛素治疗的患者死亡率显著增加,而在血糖控制不佳(HbA1c≥7.0%)的患者中,这种相关性并不显著。
与 OHA 相比,胰岛素治疗与死亡率增加相关。胰岛素治疗尤其有害,特别是在 HbA1c 水平较低的患者中,这可能表明在 HF 患者中使用胰岛素时需要特定的管理策略和血糖目标。